Internal Medicine, Endocrinology, Diabetes, & Metabolism · Los Angeles, CA
NPI
1154493674
Since 2006
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
2
Hospital affiliations
8700 Beverly Blvd.
Los Angeles, CA, 90051
Phone (310) 967-1884
Groups this clinician bills Medicare through
Medicare paid, 2024
$87K
1,080 services
Medicare patients, 2024
542
Average age 71
Drug cost, 2024
$2.0M
4,073 prescriptions
Company payments, 2025
$44K
From 4 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Run Yu was code 99214 (office e&m - established), 586 times for 328 patients. In total Run Yu billed 1,080 services in 18 codes, and Medicare paid $87K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2024-12-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Facility | 586 | 328 | $71.97 | $42K |
| 99232 Hospital E&M - Subsequent | Facility | 142 | 51 | $65.09 | $9,243 |
| 99215 Office E&M - Established | Facility | 133 | 100 | $109.61 | $15K |
| 99204 Office E&M - New | Facility | 61 | 61 | $93.66 | $5,713 |
| 99222 Hospital E&M - Initial | Facility | 58 | 55 | $107.48 | $6,234 |
| 99214 Office E&M - Established | Office | 38 | 34 | $97.58 | $3,708 |
| 99442 Telephone Services | Facility | 16 | 15 | $54.42 | $871 |
| 99215 Office E&M - Established | Office | 12 | 12 | $149.29 | $1,791 |
| 99205 Office E&M - New | Facility | 11 | 11 | $136.13 | $1,497 |
By year: 2022 $123K for 1,511 services; 2023 $90K for 1,128 services; 2024 $87K for 1,080 services.
Medicare prescription drug claims, 2024
In 2024, the drug Run Yu prescribed most often to Medicare patients was Ozempic (Semaglutide), with 323 prescriptions and refills. In total Run Yu wrote 4,073 Medicare prescriptions that cost $2.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 323 | 595 | 78 | $554K |
| Metformin Hcl Generic | 285 | 770 | 86 | $2,403 |
| Levothyroxine Sodium Generic | 274 | 727 | 73 | $2,686 |
| Metformin Hcl Er Metformin Hcl | 227 | 577 | 68 | $2,170 |
| Jardiance Empagliflozin | 213 | 488 | 57 | $277K |
| Januvia Sitagliptin Phosphate | 191 | 411 | 52 | $210K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 174 | 454 | 63 | $21K |
| Alendronate Sodium Generic | 165 | 373 | 43 | $1,944 |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 129 | 318 | 56 | $16K |
| Synthroid Levothyroxine Sodium | 109 | 283 | 26 | $9,814 |
| Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog | 92 | 191 | 23 | $40K |
| Glipizide Er Glipizide | 91 | 253 | 33 | $918 |
| Repaglinide Generic | 84 | 204 | 23 | $3,371 |
| Tradjenta Linagliptin | 82 | 187 | 22 | $89K |
| Mounjaro Tirzepatide | 77 | 87 | 13 | $90K |
Brand drugs: 1,982 claims; generic drugs: 1,790 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Run Yu $44K ($44K in general payments such as food, travel and fees) from 4 companies. The largest payer was Neurocrine BioSciences, Inc. with $42K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.